Changes in T-cell Response During Early Alzheimer's Disease Stages

Overview

This study characterizes adaptive immune changes in early Alzheimer's disease (AD), revealing a CD4+ T helper cell response to amyloid-β in preclinical AD and increased pro-inflammatory CD8+ TEMRA cells in mild cognitive impairment (MCI). These findings suggest distinct immune profiles at different early AD stages with potential therapeutic implications.

Background

Alzheimer's disease is a neurodegenerative disorder marked by amyloid-β plaques, tau pathology, and neurodegeneration, progressing from a long asymptomatic preclinical phase to mild cognitive impairment and dementia. Adaptive immunity, particularly T-cell responses, has been implicated in AD pathogenesis, but the antigenic targets and roles of these immune responses remain unclear. Prior studies identified increased CD8+ TEMRA cells in AD patients and CD4+ T-cell reactivity to amyloid-β peptides, suggesting immune involvement early in disease progression.

Data Highlights

Key Findings

• Preclinical AD subjects mount a CD4+ T helper cell response targeting amyloid-β peptides, particularly C-terminal and mid-sequence regions.
• There is an early enrichment of CD8+ T effector memory cells re-expressing CD45RA (TEMRA) in the cerebrospinal fluid during preclinical AD.
• Peripheral regulatory T cells in preclinical AD exhibit a less immunosuppressive gene signature compared to controls.
• In MCI due to AD, frequencies of CD8+ TEMRA/effector cells increase in peripheral blood with a pro-inflammatory gene expression profile.
• Antigen responsiveness generally decreases in MCI, contrasting with the active CD4+ T-cell responses seen in preclinical AD.
• The data suggest a potentially beneficial role of CD4+ T-cell activation in preclinical AD and a potentially harmful role of CD8+ T cells in MCI.

Clinical Implications

These findings highlight the complexity of adaptive immune changes in early AD and suggest that therapeutic strategies might differ by disease stage. Enhancing specific CD4+ T-cell responses could be beneficial in the preclinical phase, while targeting pro-inflammatory CD8+ T-cell activity may be important in MCI to mitigate potential harmful effects. Immune profiling could aid in refining early interventions and biomarker development.

Conclusion

The study demonstrates distinct adaptive immune alterations in early AD stages, with CD4+ T-cell responses prominent in preclinical AD and pro-inflammatory CD8+ T-cell changes in MCI. These insights provide a foundation for stage-specific immunomodulatory approaches in Alzheimer's disease.

References

1. Skelly et al. 2021 -- Scientific Commentary on T-cell Responses in AD